Figure 5 –

Zafirlukast inhibits the growth of OVCAR-8 tumors on xenograft mice. (A) NOG mice were SC injected with OVCAR8 cells at 4 weeks old (n=13/group). Tumors were allowed to grow to an average size of 30 mm³ before daily treatment with 30 mg/kg of zafirlukast (red bars) or vehicle control (black bars). Tumor size was measured twice weekly. Data is presented as mean ±SD. A student’s t-test where *p=0.0149 at 18 days, ***p=0.0002 at 21 and 25 days, ****p<0.0001 at 28 days and ***p=0.0001 at 28 days. (B) PDI and ERp57 levels in tumors were measured by immunoblotting after day 32 of treatment in control vs zafirlukast treated mice with minimal difference in expression. (C. & D) Lung metastasis (n=4/group) were graded on a scale of 0–4. A significant difference was seen between the control and zafirlukast treated groups. Data is presented as mean ±SD. A student’s t-test where ***p=0.0004 for the treated group compared to the control. (E) Similar to A, except mice were treated with 5 mg/kg cisplatin and 120 mg/kg gemcitabine once weekly in the presence (red bars) or absence (black bars) of 30 mg/kg zafirlukast daily (n=12/group). Data is presented as mean ±SD. A student’s t-test where *p=0.023, 0.012, 0.018 and 0.027 for days 14, 18, 21 and 25 respectively, and **p=0.004 for day 28. (F) A summary of the three different treatment groups, normalized to the control group by percentage.